NCT01802879 - Study to Allow Access to Single Agent Panobinostat for Patients Who Are on s.a. Panobinostat Treatment in a Novartis-sponsored Study and Continue to Benefit From the Treatment as Judged by the Investigator | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 24, 2013

Primary Completion Date

November 19, 2018

Study Completion Date

November 19, 2018

Conditions

Hematologic Neoplasms

Interventions

DRUG

Panobinostat

Panobinostat was provided as 5, 10 and 20 mg hard gelatin capsules to be taken orally. Patients started on dose from parent protocol and dose modifications were at the discretion of the investigator based on guidance provided in the protocol and IB.

Trial Locations (7)

30912

Georgia Regents University SC-2, Augusta

37007

Novartis Investigative Site, Salamanca

84103

University of Utah / Huntsman Cancer Institute SC-2, Salt Lake City

91120

Novartis Investigative Site, Jerusalem

91010 3000

City of Hope National Medical Center Dept.ofCityofHopeMedicalCtr(1), Duarte

02215

Dana Farber Cancer Institute Reg. Ped, Boston

2300 RC

Novartis Investigative Site, Leiden